Welcome to our dedicated page for ACARIX news (Ticker: ACARIX), a resource for investors and traders seeking the latest updates and insights on ACARIX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACARIX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACARIX's position in the market.
Acarix (Nasdaq First North: ACARIX, OTCQB: ACIXF) announced that its CADScor® System has received regulatory approval from the Emirates Drug Establishment and the UAE Ministry of Health and Prevention, enabling commercial availability across the United Arab Emirates through partner UniTech Solutions.
The approval marks Acarix's entry into the Gulf region and a platform for broader GCC expansion. The CADScor System is a point-of-care diagnostic aid that uses acoustics, computational analysis, and AI to assess coronary blood flow and help rule out significant coronary artery disease in under 10 minutes, with at least 96% negative predictive value. The technology is CE-marked, FDA De Novo cleared, backed by over 15 years of R&D, 45 patents, and usage in more than 60,000 patient assessments.